drugset
drugset / Trial / NCT04220190

RAPA-501 Therapy for ALS

NCT04220190 ↗

Phase 2/3 Recruiting 41 enrolled Rapa Therapeutics LLC Massachusetts General Hospital · collab
NaSingle-groupOpen-labelTreatment

Summary

RAPA-501-ALS is a phase 2/3 expansion cohort study of RAPA-501 autologous hybrid TREG/Th2 cells in patients living with amyotrophic lateral sclerosis (pwALS).

Timeline

Start
2025-01-02
Primary completion
2026-07-01
Completion
2027-06-01

Drugs

EvaluationDrugModalityDoseRoute
Subject RAPA-501 Cell therapy 8e+07 cells —

Indications

amyotrophic lateral sclerosis